162 related articles for article (PubMed ID: 38402182)
21. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
22. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
23. Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment.
Dong C; Cheng W; Zhang M; Li S; Zhao L; Chen D; Qin Y; Xiao M; Fang S
Front Oncol; 2022; 12():992596. PubMed ID: 36324591
[TBL] [Abstract][Full Text] [Related]
24. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
26. Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer.
Shen H; Du G; Liu Z; Bao J; Yu Q; Jia C; Liang X; Shan L
Int J Clin Exp Med; 2015; 8(12):22300-9. PubMed ID: 26885207
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features and prognostic analysis of 77 patients with multiple primary cancers.
Zheng R; Li H; Ye Y; Guan L; Li H; Ye Z; Yuan G; Zhang X; Wang G; Cao M; Zhang R; Jiang B
J BUON; 2020; 25(4):2110-2116. PubMed ID: 33099961
[TBL] [Abstract][Full Text] [Related]
29. Clinical features and outcomes of patients with stage I multiple primary lung cancers.
Shintani Y; Okami J; Ito H; Ohtsuka T; Toyooka S; Mori T; Watanabe SI; Asamura H; Chida M; Date H; Endo S; Nagayasu T; Nakanishi R; Miyaoka E; Okumura M; Yoshino I;
Cancer Sci; 2021 May; 112(5):1924-1935. PubMed ID: 33236385
[TBL] [Abstract][Full Text] [Related]
30. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
Yang CY; Shih JY; Liao WY; Ho CC; Hsu CL; Tsai TH; Wu SG; Lin YT; Hsu WH; Jain S; Olsen S; Yang JC; Yu CJ; Yang PC
Eur J Cancer; 2023 Nov; 193():113310. PubMed ID: 37722270
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathological characteristics and prognosis of patients with small bowel tumors: A single center analysis of 220 cases].
Liao XL; Zhu YF; Zhang WH; Chen XL; Liu K; Zhao LY; Yang K; Hu JK
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):467-474. PubMed ID: 37217355
[No Abstract] [Full Text] [Related]
32. [Comparison of clinicopathological features and prognosis between left-sided colon cancer and right-sided colon cancer].
Gao X; Yu G; Liu P; Hao L; Liu L; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):647-653. PubMed ID: 28643309
[TBL] [Abstract][Full Text] [Related]
33. Clinical Pathological Characteristics and Prognosis of Multigene Co-Mutations in Elderly Patients With Non-Small Cell Lung Cancer: A Retrospective Analysis.
Li W; Chang F; Zhang H; Meng F; Ke Z; Zhang Y
Clin Med Insights Oncol; 2023; 17():11795549231211505. PubMed ID: 38033742
[TBL] [Abstract][Full Text] [Related]
34. Genetic features and application value of next generation sequencing in the diagnosis of synchronous multifocal lung adenocarcinoma.
Chen X; Lu J; Wu Y; Jiang X; Gu Y; Li Y; Zhao H; Jin M
Oncol Lett; 2020 Sep; 20(3):2829-2839. PubMed ID: 32782601
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy.
Li H; Wang C; Wang Z; Hu Y; Zhang G; Zhang M; Zheng X; Zhang X; Yang J; Ma Z; Wang H
Lung Cancer; 2019 Apr; 130():42-49. PubMed ID: 30885350
[TBL] [Abstract][Full Text] [Related]
36. Bidirectional Mendelian randomization analysis of the genetic association between primary lung cancer and colorectal cancer.
Xiao Z; Wang Z; Zhang T; Liu Y; Si M
J Transl Med; 2023 Oct; 21(1):722. PubMed ID: 37840123
[TBL] [Abstract][Full Text] [Related]
37. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
[TBL] [Abstract][Full Text] [Related]
38. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.
Yu X; Si J; Wei J; Wang Y; Sun Y; Jin J; Zhang X; Ma T; Song Z
Cancer Med; 2023 Mar; 12(5):5630-5638. PubMed ID: 36380563
[TBL] [Abstract][Full Text] [Related]
39. Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component.
Zhang S; Xu Y; Zhao P; Bao H; Wang X; Liu R; Xu R; Xiang J; Jiang H; Yan J; Wu X; Shao Y; Liang J; Wu Q; Zhang Z; Lu S; Ma S
Front Oncol; 2021; 11():652193. PubMed ID: 34221970
[TBL] [Abstract][Full Text] [Related]
40. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
